Colchicine in patients with acute coronary syndrome: the Australian COPS randomized clinical trial
DC Tong, S Quinn, A Nasis, C Hiew… - Circulation, 2020 - Am Heart Assoc
Background: Inflammation plays a crucial role in clinical manifestations and complications of
acute coronary syndromes (ACS). Colchicine, a commonly used treatment for gout, has …
acute coronary syndromes (ACS). Colchicine, a commonly used treatment for gout, has …
Efficacy and safety of low-dose colchicine after myocardial infarction
JC Tardif, S Kouz, DD Waters… - New England journal …, 2019 - Mass Medical Soc
Background Experimental and clinical evidence supports the role of inflammation in
atherosclerosis and its complications. Colchicine is an orally administered, potent …
atherosclerosis and its complications. Colchicine is an orally administered, potent …
Efficacy and safety of low-dose colchicine in patients with coronary disease: a systematic review and meta-analysis of randomized trials
ATL Fiolet, TSJ Opstal, A Mosterd… - European Heart …, 2021 - academic.oup.com
Aims Recent randomized trials demonstrated a benefit of low-dose colchicine added to
guideline-based treatment in patients with recent myocardial infarction or chronic coronary …
guideline-based treatment in patients with recent myocardial infarction or chronic coronary …
Colchicine in patients with chronic coronary disease in relation to prior acute coronary syndrome
TSJ Opstal, ATL Fiolet, A van Broekhoven… - Journal of the American …, 2021 - jacc.org
Background Colchicine reduces risk of cardiovascular events in patients post–myocardial
infarction and in patients with chronic coronary disease. It remains unclear whether this …
infarction and in patients with chronic coronary disease. It remains unclear whether this …
Colchicine for acute and chronic coronary syndromes
Colchicine is an ancient drug, traditionally used for the treatment and prevention of gouty
attacks; it has become standard of treatment for pericarditis with a potential role in the …
attacks; it has become standard of treatment for pericarditis with a potential role in the …
Time-to-treatment initiation of colchicine and cardiovascular outcomes after myocardial infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT)
N Bouabdallaoui, JC Tardif, DD Waters… - European heart …, 2020 - academic.oup.com
Abstract Aims The COLchicine Cardiovascular Outcomes Trial (COLCOT) demonstrated the
benefits of targeting inflammation after myocardial infarction (MI). We aimed to determine …
benefits of targeting inflammation after myocardial infarction (MI). We aimed to determine …
[HTML][HTML] Colchicine in patients with chronic coronary disease
SM Nidorf, ATL Fiolet, A Mosterd… - New England journal …, 2020 - Mass Medical Soc
Background Evidence from a recent trial has shown that the antiinflammatory effects of
colchicine reduce the risk of cardiovascular events in patients with recent myocardial …
colchicine reduce the risk of cardiovascular events in patients with recent myocardial …
The low dose colchicine after myocardial infarction (LoDoCo-MI) study: a pilot randomized placebo controlled trial of colchicine following acute myocardial infarction
T Hennessy, L Soh, M Bowman, R Kurup, C Schultz… - American heart …, 2019 - Elsevier
Background Following an acute myocardial infarction (MI), patients with persistently
elevated biomarkers of inflammation, in particular C-reactive protein (CRP), are at …
elevated biomarkers of inflammation, in particular C-reactive protein (CRP), are at …
Cost-effectiveness of low-dose colchicine after myocardial infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT)
M Samuel, JC Tardif, P Khairy, F Roubille… - … Journal-Quality of …, 2021 - academic.oup.com
Aims In the randomized, placebo-controlled Colchicine Cardiovascular Outcomes Trial
(COLCOT) of 4745 patients enrolled within 30 days after myocardial infarction (MI), low-dose …
(COLCOT) of 4745 patients enrolled within 30 days after myocardial infarction (MI), low-dose …
Colchicine in patients with coronary artery disease: a systematic review and meta‐analysis of randomized trials
Background Inflammation plays a pivotal role in coronary artery disease (CAD). The anti‐
inflammatory drug colchicine seems to reduce ischemic events in patients with CAD. So far …
inflammatory drug colchicine seems to reduce ischemic events in patients with CAD. So far …